INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
University of Tübingen
Tubinga, AlemaniaPublicaciones en colaboración con investigadores/as de University of Tübingen (38)
2024
-
Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715
-
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202
2023
-
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
Bone Marrow Transplantation, Vol. 58, Núm. 11, pp. 1182-1188
-
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
Advances in Therapy, Vol. 40, Núm. 5, pp. 2412-2425
-
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Blood cancer journal
-
Enhancing Adaptive Teaching of Reading Skills Using Digital Technologies: The LATILL Project
Lecture Notes in Educational Technology (Springer Science and Business Media Deutschland GmbH), pp. 1092-1098
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
Haematologica
2022
-
Doublecortin in the Fish Visual System, a Specific Protein of Maturing Neurons
Biology, Vol. 11, Núm. 2
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282
-
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505
2021
-
1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans
Translational psychiatry, Vol. 11, Núm. 1, pp. 182
-
Cultures of glial cells from optic nerve of two adult teleost fish: Astatotilapia burtoni and Danio rerio
Journal of Neuroscience Methods, Vol. 353
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT
Bone Marrow Transplantation, Vol. 56, Núm. 2, pp. 481-491
2020
-
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
Clinical and Translational Science, Vol. 13, Núm. 6, pp. 1345-1354
2019
-
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
Haematologica, Vol. 104, Núm. 5, pp. 929-936
-
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
The Lancet, Vol. 393, Núm. 10168, pp. 253-264
-
Sox2 expression in the visual system of two teleost species
Brain Research, Vol. 1722
2018
-
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR
Haematologica, Vol. 103, Núm. 12, pp. 2079-2087
-
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network
Leukemia, Vol. 32, Núm. 7, pp. 1542-1560